clarithromycin has been researched along with Immunoglobulin Light-chain Amyloidosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avni, B; Barshay, Y; Benyamini, N; Ganzel, C; Gatt, ME; Goldschmidt, N; Gural, A; Lavie, D; Libster, D; Shaulov, A | 1 |
1 other study(ies) available for clarithromycin and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Disease Progression; Fatigue; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Infections; Male; Middle Aged; Multiple Myeloma; Protein Synthesis Inhibitors; Recurrence; Salvage Therapy; Treatment Outcome | 2017 |